Börsennachrichten
Aktuelle Finanznachrichten · Aktualisiert Jul 18, 2026
Medicus Pharma Ltd. (MDCXW) meldet FDA-Fortschritte und erweitert den Ausblick für 2026
Medicus Pharma Ltd. (MDCXW) Reports FDA Progress and Expands 2026 Clinical Outlook
Medicus Pharma (MDCXW) faces acute financing pressure with only 2 quarters of runway, despite recent clinical progress. Dilution is likely …
MicroVision, Inc. (MVIS) schließt Partnerschaft mit Avular zur Weiterentwicklung autonomer Drohnensysteme
MicroVision, Inc. (MVIS) Partners With Avular to Advance Autonomous Drone Systems
The panel is bearish on MicroVision (MVIS) due to high execution risk, lack of binding commitments, and intense competition in …
Ist Faraday Future Intelligent Electric Inc. (FFAI) ein aufstrebender KI-Robotik-Stock, den man 2026 im Auge behalten sollte?
Is Faraday Future Intelligent Electric Inc. (FFAI) Emerging as an AI Robotics Stock to Watch in 2026?
The panel consensus is overwhelmingly bearish on FFAI's current trajectory, citing microscopic revenue, heavy cash burn, and questionable execution capabilities …
Entwickelt sich Cycurion, Inc. (CYCU) bis 2026 zu einem wachstumsstarken Cybersecurity-Unternehmen mit hohen Margen?
Is Cycurion, Inc. (CYCU) Emerging as a High-Margin Cybersecurity Growth Stock in 2026?
The panel consensus is bearish on CYCU, with the main takeaway being that the company's bullish revenue visibility narrative relies …
Nicht viel Nvidia? Für diesen Halbleiter-ETF kein Problem
Not Much Nvidia? It's No Problem for This Semiconductor ETF
The panel discusses the outperformance of XSD, an equal-weighted semiconductor ETF, with mixed views on its sustainability and risks. While …
Lake Street kürzt Kursziel für Cardlytics, Inc. (CDLX) auf 1,25 $ angesichts angepasster Erwartungen
Lake Street Cuts Cardlytics, Inc. (CDLX) Price Target to $1.25 Amid Reset Expectations
The panel consensus is that CDLX is in a dire financial situation, with significant revenue declines, negative free cash flow, …
Warum der Kursziel von Humacyte, Inc. (HUMA) trotz der frühen kommerziellen Phase erhöht wurde
Why Humacyte, Inc. (HUMA) Price Target Was Raised Despite Early-Stage Commercialization
The panel consensus is bearish on Humacyte's stock, with concerns about heavy cash burn, negligible revenue, and uncertainty around strategic …
Warum wurde das Kursziel für Heron Therapeutics, Inc. (HRTX) auf 4 $ bei H.C. Wainwright gesenkt?
Why Heron Therapeutics, Inc. (HRTX) Price Target Was Reduced to $4 at H.C. Wainwright?
The panelists agree that Heron Therapeutics' (HRTX) financial outlook is uncertain, with a key risk being the slow adoption of …
Kann Definitive Healthcare Corp. (DH) nach angepasstem Kursziel von Baird Stabilität wahren?
Can Definitive Healthcare Corp. (DH) Maintain Stability After Revised Price Target From Baird?
The panel consensus is bearish, with concerns about Definitive Healthcare's (DH) revenue contraction and uncertainty around its customer retention and …
Standard Chartered übernimmt Zodia Custody
Standard Chartered to acquire Zodia Custody
Standard Chartered's deal to fold Zodia Custody into its core business and spin out Zodia Solutions as a multi-bank backed …
Morning Bid: Waffenstillstand am Messerrücken
Morning Bid: Ceasefire on a knife edge
Despite Trump's Iran de-escalation comments, markets remain cautious due to structural oil supply tightness and potential energy inflation. The NextEra-Dominion …
Warum Analysten glauben, dass die Wachstumsgeschichte von Boost Run (BRUN) noch am Anfang stehen könnte
Why Analysts Believe Boost Run’s (BRUN) Growth Story May Still Be Early
Panelists largely agree that BRUN's recent analyst upgrades are overhyped, with significant execution risks and potential market headwinds outweighing the …